The Role of 68Ga-DOTA-SSA PET/CT in the Management and Prediction of Peptide Receptor Radionuclide Therapy Response for Patients With Neuroendocrine Tumors
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Nuclear Medicine"
DOI: 10.1097/rlu.0000000000004235
Abstract: Purpose The aim of this study was to identify and evaluate the role of 68Ga-DOTA–somatostatin analog (SSA) PET/CT in guiding treatment for patients with neuroendocrine tumors (NETs) based on published literature, with specific focus on… read more here.
Keywords: dota ssa; management; ssa pet; 68ga dota ... See more keywords
Clinical impact of using [18F]AlF‐NOTA‐octreotide PET/CT instead of [68Ga]Ga‐DOTA‐SSA PET/CT: Secondary endpoint analysis of a multicenter, prospective trial
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Neuroendocrinology"
DOI: 10.1111/jne.13420
Abstract: [18F]AlF‐NOTA‐octreotide ([18F]AlF‐OC) is a promising alternative for [68Ga]Ga‐DOTA‐somatostatin analogs (SSAs) in positron emission tomography (PET) imaging of the somatostatin receptor (SSTR). Our aim is to assess changes in TNM staging and differences in patient management… read more here.
Keywords: pet; dota ssa; 18f alf; 68ga dota ... See more keywords